Motif Pharmaceuticals Ltd. - Feb 15, 2024 Form 3 Insider Report for Chromocell Therapeutics Corp (CHRO)

Role
10%+ Owner
Signature
Motif Pharmaceuticals Ltd., By /s/ Zachary Klein
Stock symbol
CHRO
Transactions as of
Feb 15, 2024
Transactions value $
$0
Form type
3
Date filed
2/15/2024, 08:36 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CHRO Common Stock 471K Feb 15, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CHRO Senior Secured Convertible Promissory Note Feb 15, 2024 Common Stock 12.7K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents $61,109.98 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which will automatically convert into 12,732 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.
F2 Zachary Klein has sole voting and dispositive power over the shares held by the Reporting Person as to which Mr. Klein disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Remarks:

Exhibit 24 - Power of Attorney